EUCTR2016-002360-14-DK
Active, not recruiting
Phase 1
Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer
Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET0 sites90 target enrollmentJuly 27, 2016
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET
- Enrollment
- 90
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to understand patient information and to give informed consent
- •Not previously irradiated or operated on neck
- •OSCC or OPSCC cN0 verified histologically by pathologic examination of biopsy
- •OSCC or OPSCC N \+ verified histologically by pathologic examination of biopsy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 35
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 55
Exclusion Criteria
- •Pregnancy
- •Patients who are candidates for curative intentional radiation
- •Patients who have had surgery or radiation therapy to the neck as this may alter the lymph drainage.
- •Other diseases assessed by the investigator as basis for exclusion.
- •Age under 18 or over 85 years
- •Obesity\> 140 kg
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
uPAR PET/CT og FDG PET/CT til præoperativ stadieinddeling af patienter med nydiagnosticeret Gynækologisk Kræftgynecological cancers:Vulvar cancerendometrial cancer (uterine cancer)cervical cancerovarian cancerMedDRA version: 20.0Level: LLTClassification code 10007107Term: Cancer of ovarySystem Organ Class: 100000021045MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000020935MedDRA version: 20.0Level: LLTClassification code 10047743Term: Vulval cancer NOSSystem Organ Class: 100000021101MedDRA version: 20.0Level: LLTClassification code 10007063Term: Cancer of endometriumSystem Organ Class: 100000021008MedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000020977Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]EUCTR2016-004638-99-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET350
Completed
Phase 2
A clinical trial to see whether outcomes in Hodgkins Lymphoma can be improved by using increased intensity therapy in interim PET scan positive patientsHealth Condition 1: null- Advanced Hodgkins Lymphoma (Stage IIb, III, IV)Health Condition 2: C819- Hodgkin lymphoma, unspecifiedHealth Condition 3: C819- Hodgkin lymphoma, unspecifiedCTRI/2012/06/002741Cancer Institute50
Active, not recruiting
Phase 1
Phase II trial: uPAR PET/CT and FDG PET/MRI for determining lymph node metastases in patients with bladder cancerrinary bladder cancerMedDRA version: 19.0Level: LLTClassification code 10005004Term: Bladder cancer NOSSystem Organ Class: 100000004864Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]EUCTR2016-001026-33-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET40
Active, not recruiting
Phase 1
uPAR-PET - a new method for determining lymph node metastases in breast cancer patientsbreast cancerMedDRA version: 18.1Level: LLTClassification code 10006192Term: Breast cancer NOSSystem Organ Class: 100000004864Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]EUCTR2015-004503-23-DKRigshospitalet, Department of Clinical Physiology, Nucelar Medicine and PET
Active, not recruiting
Phase 2
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast CancerBreast CancerNCT01937117Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins88